A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community.
The article presents a method to estimate the level of factor VIII (FVIII) concentrate consumption and economic capacity for each of the 110 countries considered in the study. A number of health-economic indicators were examined and purchasing power parity (PPP) gross national income (GNI) per capita had the strongest correlation with amount of FVIII concentrates sold in a country. Available data on FVIII concentrate consumption and health-economic indicators were used to calculate index values for FVIII use and economic capacity so each country can assess and compare its level of FVIII concentrate consumption with the economic resources of other countries in the global haemophilia A community. This article is of importance to policy makers, care givers and patient organizations in planning health-care resources for the treatment of haemophilia.
Stonebraker
J S
JS
Bayer Biological Products, 4101 Research Commons, Alexander Drive, Research Triangle Park, NC 27709-3387, USA. jeff.stonebraker.b@bayer.com
Amand
R E
RE
Nagle
A J
AJ
D003906:Developing Countries / Q000191:economics*; D004363:Drug Utilization; D005169:Factor VIII / Q000008:administration & dosage*; D017048:Health Care Costs; D015276:Health Care Rationing; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007182:Income; D008297:Male
D005169:Factor VIII